50596-37-7

Basic information

• Product Name: methyl 4-(pyridin-2-ylmethoxy)benzoate
• Synonyms: methyl 4-(pyridin-2-ylmethoxy)benzoate
• CAS NO: 50596-37-7
• Molecular Weight: 243.262
• Mol File: 50596-37-7.mol

Chemical Properties

• CAS DataBase Reference: methyl 4-(pyridin-2-ylmethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(pyridin-2-ylmethoxy)benzoate(50596-37-7)
• EPA Substance Registry System: methyl 4-(pyridin-2-ylmethoxy)benzoate(50596-37-7)

Safety Data

• Hazardous Substances Data: 50596-37-7(Hazardous Substances Data)

Upstream product

• 31106-82-8 2-(bromomethyl)pyridine hydrobromide 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 586-98-1 2-Hydroxymethylpyridine 

Downstream Products

• 50596-34-4 (4-(pyridin-2-ylmethoxy)-phenyl)-methanol 
• 50596-36-6 4-(pyridin-2-ylmethoxy)benzoic acid 

Relevant articles and documents

FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1

The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME

The present invention provides an antifungal agent that has excellent antifungal action, and is also excellent in terms of its properties, safety, and metabolic stability. The present invention discloses a compound represented by the following formula I or a salt thereof, and an antifungal agent comprising the compound or the salt: wherein R1 represents a hydrogen atom, a halogen atom, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6-alkoxy-C1-6-alkyl group; R2 represents a hydrogen atom or an amino group; X, Y, Z, and W independently represent a nitrogen atom, an oxygen atom, a sulfur atom, or -CH-, provided that at least two among X, Y, and W are nitrogen atoms; the ring A represents a 5- or 6-membered heteroaryl ring or a benzene ring; Q represents a methylene group, an oxygen atom, -CH2O-, -OCH2-, -NH-, -NHCH2-, or -CH2NH-; and R3 represents a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, or a 5- or 6-membered heteroaryl group, each of which may have one or two substituents.

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the